Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-ONE neoadjuvant hormonal therapy before brachytherapy in localized prostate cancer
NL-OMON39212Not yet recruiting
- Sponsor
- TweeSteden Ziekenhuis
- Start
- Feb 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of leuprolide and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by TweeSteden Ziekenhuis. Primary endpoints: PSA levels over 3 years and Testosterone levels over 3 years. Planned start Feb 2012; status: not yet recruiting.
02
Drugs
leuprolidebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON39212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39212.